{"analyses":[{"groupDescription":"PedsQL v.3.0 Total Score-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Total Score-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Total Score-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.067","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Pain and Hurt-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.115","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Pain and Hurt-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.455","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Pain and Hurt-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.636","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Nausea-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Nausea-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Nausea-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.006","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Procedural Anxiety-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.099","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Procedural Anxiety-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.050","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Procedural Anxiety-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.520","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Treatment Anxiety-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.024","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Treatment Anxiety-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.011","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Treatment Anxiety-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.009","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Worry-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Worry-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Worry-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.035","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Cognitive Problems-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.037","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Cognitive Problems-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.043","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Cognitive Problems-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.044","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Perceived Physical Appearance-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.091","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Perceived Physical Appearance-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.248","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Perceived Physical Appearance-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.069","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Communication-T2, completion of 2 cycles of chemotherapy (approximately 2 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.010","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Communication-T3, completion of 4 cycles of chemotherapy (approximately 4 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.292","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"PedsQL v.3.0 Communication-T4, completion of radiation (approximately 8 months)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.429","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.97","value":"73.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Total Score-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.68","value":"80.41"},{"groupId":"OG001","spread":"14.58","value":"71.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"PedsQL v.3.0 Total Score-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.87","value":"83.33"},{"groupId":"OG001","spread":"17.72","value":"73.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"PedsQL v.3.0 Total Score-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.62","value":"85.33"},{"groupId":"OG001","spread":"16.25","value":"79.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"PedsQL v.3.0 Total Score-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.45","value":"73.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Pain and Hurt-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.94","value":"71.77"},{"groupId":"OG001","spread":"27.49","value":"66.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Pain and Hurt-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.03","value":"72.63"},{"groupId":"OG001","spread":"29.34","value":"69.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Pain and Hurt-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.3","value":"77.5"},{"groupId":"OG001","spread":"25.39","value":"82.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"PedsQL v.3.0 Pain and Hurt-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.2","value":"73.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Nausea-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.92","value":"75.52"},{"groupId":"OG001","spread":"23.83","value":"60.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Nausea-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.73","value":"79.66"},{"groupId":"OG001","spread":"26.92","value":"60.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Nausea-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.67","value":"88.1"},{"groupId":"OG001","spread":"22.69","value":"78.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"PedsQL v.3.0 Nausea-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"58.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Procedural Anxiety-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.64","value":"77.55"},{"groupId":"OG001","spread":"27.72","value":"71.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Procedural Anxiety-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.47","value":"81.61"},{"groupId":"OG001","spread":"27.98","value":"73.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"PedsQL v.3.0 Procedural Anxiety-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.36","value":"76.83"},{"groupId":"OG001","spread":"24.2","value":"77.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"PedsQL v.3.0 Procedural Anxiety-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.47","value":"84.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Treatment Anxiety-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.67","value":"91.39"},{"groupId":"OG001","spread":"17.06","value":"85.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Treatment Anxiety-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.37","value":"93.97"},{"groupId":"OG001","spread":"23.11","value":"85.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Treatment Anxiety-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.95","value":"93.17"},{"groupId":"OG001","spread":"22.9","value":"83.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"PedsQL v.3.0 Treatment Anxiety-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.08","value":"69.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Worry-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.51","value":"77.55"},{"groupId":"OG001","spread":"25.01","value":"64.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"PedsQL v.3.0 Worry-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.01","value":"84.2"},{"groupId":"OG001","spread":"25.33","value":"66.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Worry-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.89","value":"82.17"},{"groupId":"OG001","spread":"29.58","value":"69.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"PedsQL v.3.0 Worry-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.09","value":"72.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Cognitive Problems-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.06","value":"81.25"},{"groupId":"OG001","spread":"19.48","value":"75.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"PedsQL v.3.0 Cognitive Problems-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.41","value":"84.38"},{"groupId":"OG001","spread":"22.03","value":"78.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Cognitive Problems-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.95","value":"87.04"},{"groupId":"OG001","spread":"17.84","value":"81.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"PedsQL v.3.0 Cognitive Problems-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.21","value":"79.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Perceived Physical Appearance-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.99","value":"83.53"},{"groupId":"OG001","spread":"24.91","value":"78.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Perceived Physical Appearance-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.29","value":"82.69"},{"groupId":"OG001","spread":"22.47","value":"79.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Perceived Physical Appearance-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.48","value":"85.17"},{"groupId":"OG001","spread":"23.79","value":"79.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"PedsQL v.3.0 Perceived Physical Appearance-T4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.3","value":"74.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"PedsQL v.3.0 Communication-T1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.73","value":"85.38"},{"groupId":"OG001","spread":"18.58","value":"79.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"PedsQL v.3.0 Communication-T2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.9","value":"85.34"},{"groupId":"OG001","spread":"21.22","value":"81.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"PedsQL v.3.0 Communication-T3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.6","value":"87.33"},{"groupId":"OG001","spread":"21.16","value":"84.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"PedsQL v.3.0 Communication-T4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"Assess and compare the patient reported quality of life and symptom distress to that of patients treated on the HOD99 unfavorable risk 2 arm (UR2) using the Peds Quality of Life version 3. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. For both the total score and subscales the range is 0-100. The total score is the sum of all items from each subscale, over the number of items answered on the scale. The total score is the sum of all items on the scale over the number of items answer. If \\>50% of the items are missing the score should not be computed. If \\>50% are completed, impute the mean of the completed items in a scale. The Higher the score the better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Ann Arbor stage IIB, IIIB, IVA, or IVB risk participants received 2 cycles of AEPA/CAPDac chemotherapy and reported symptoms distress scale (SDS).","id":"OG000","title":"AEPA/CAPDac"},{"description":"Ann Arbor stage IIB, IIIB, or any IV risk participants received 12 weeks Stanford V Chemotherapy","id":"OG001","title":"HOD99 Unfavorable Risk 2 Arm (UR2)"}],"paramType":"MEAN","populationDescription":"Each institution made the decision whether to complete the QoL objective. Participation in the Quality of Life part of the trial is voluntary for participating institutions and voluntary by patient. The Peds QL 3.0 data was not collected on the HOD 99 patients at the T1 time point.","reportingStatus":"POSTED","timeFrame":"At Diagnosis (baseline) (T1), completion of 2 cycles of chemotherapy (approximately 2 months) (T2), completion of 4 cycles of chemotherapy (approximately 4 months) (T3), completion of radiation (approximately 8 months) (T4)","title":"To Assess the Patient Reported Symptoms and Health-related Quality of Life in Children With High Risk HL Compared to Those Treated on the Unfavorable HOD99 Treatment Arm (UR2) at Multiple Time Points. (PedsQL v.3.0)","type":"SECONDARY","unitOfMeasure":"score on a scale"}